Literature DB >> 17026657

High-resolution optical coherence tomography as a non-destructive monitoring tool for the engineering of skin equivalents.

F Spöler1, M Först, Y Marquardt, D Hoeller, H Kurz, H Merk, F Abuzahra.   

Abstract

BACKGROUND: Three dimensional skin equivalents are widely used in dermatopharmacological and toxicological studies and as autologous transplants in wound healing. In pharmacology, there is tremendous need for monitoring the response of engineered skin equivalents to external treatment. Transplantation of skin equivalents for wound healing requires careful verification of their quality prior to transplantation. Optical coherence tomography (OCT) is a non-contact, non-destructive imaging technique for living tissues offering the potential to fulfill these needs. This work presents an analysis of OCT for high-resolution monitoring of skin equivalents at different stages during the culture process.
METHODS: We developed a high-resolution OCT imaging setup based on a commercially available OCT system. A broadband femtosecond laser light source replaces the original superluminescence diode. Tomograms of living skin equivalents were recorded with an axial resolution of 3 mum and correlated with histology and immunofluorescence images. Comparison with standard low-resolution OCT is presented to emphasize the advantages of high-resolution OCT for this application.
RESULTS: OCT is particularly able to distinguish between different layers of skin equivalents including stratum corneum, epidermal and dermal layer as well as the basement membrane zone. The high-resolution OCT scans correlate closely with two key benchmarks, histology and immunofluorescence imaging.
CONCLUSIONS: This study clearly demonstrates the benefits of high-resolution OCT for identifying living tissue structure and morphology. Compared with the current gold standard histology, OCT offers non-destructive tissue imaging, enabling high-resolution evaluation of living tissue morphology and structure as it evolves.

Mesh:

Year:  2006        PMID: 17026657     DOI: 10.1111/j.0909-752X.2006.00163.x

Source DB:  PubMed          Journal:  Skin Res Technol        ISSN: 0909-752X            Impact factor:   2.365


  7 in total

1.  [Optical coherence tomography of the skin: a diagnostic light look].

Authors:  Faris Abuzahra; J M Baron
Journal:  Hautarzt       Date:  2006-07       Impact factor: 0.751

Review 2.  Optical spectroscopy and imaging for the noninvasive evaluation of engineered tissues.

Authors:  Irene Georgakoudi; William L Rice; Marie Hronik-Tupaj; David L Kaplan
Journal:  Tissue Eng Part B Rev       Date:  2008-12       Impact factor: 6.389

3.  Optical coherence tomography angiography monitors human cutaneous wound healing over time.

Authors:  Anthony J Deegan; Wendy Wang; Shaojie Men; Yuandong Li; Shaozhen Song; Jingjiang Xu; Ruikang K Wang
Journal:  Quant Imaging Med Surg       Date:  2018-03

4.  Full-color skin imaging using RGB LED and floating lens in optical coherence tomography.

Authors:  Bor-Wen Yang; Xin-Chang Chen
Journal:  Biomed Opt Express       Date:  2010-11-08       Impact factor: 3.732

5.  Utilization potential of intraluminal optical coherence tomography for the Eustachian tube.

Authors:  Hayoung Byun; Yeon Hoon Kim; Jingchao Xing; Su-Jin Shin; Seung Hwan Lee; Hongki Yoo; Jae Ho Chung
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

Review 6.  Role of Ceramide from Glycosphingolipids and Its Metabolites in Immunological and Inflammatory Responses in Humans.

Authors:  Kazuhisa Iwabuchi; Hitoshi Nakayama; Ami Oizumi; Yasushi Suga; Hideoki Ogawa; Kenji Takamori
Journal:  Mediators Inflamm       Date:  2015-11-01       Impact factor: 4.711

7.  Pseudomonas-derived ceramidase induces production of inflammatory mediators from human keratinocytes via sphingosine-1-phosphate.

Authors:  Ami Oizumi; Hitoshi Nakayama; Nozomu Okino; Chihiro Iwahara; Katsunari Kina; Ryo Matsumoto; Hideoki Ogawa; Kenji Takamori; Makoto Ito; Yasushi Suga; Kazuhisa Iwabuchi
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.